Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics
暂无分享,去创建一个
Peter A. J. Hilbers | Paj Peter Hilbers | Marcel de Gooyer | Luc Roumen | Koen Pieterse | Erica M. G. Custers | Ralf Plate | Ilona P. E. Beugels | Judith M. A. Emmen | Dirk Leysen | Jos F. M. Smits | Harry C. J. Ottenheijm | J. J. Rob Hermans | Marijn P. A. Sanders | P. Hilbers | L. Roumen | J. Smits | J. Emmen | H. Ottenheijm | E. Custers | J. Hermans | R. Plate | K. Pieterse | D. Leysen | M. D. Gooyer | M. Sanders | I. Beugels | Johannes Jozeph Robertus Maria Hermans
[1] J. Connell,et al. Effects of 18-hydroxylated steroids on corticosteroid production by human aldosterone synthase and 11beta-hydroxylase. , 2001, The Journal of clinical endocrinology and metabolism.
[2] G. V. Paolini,et al. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..
[3] Andrew Howard,et al. Crystal structures of metyrapone- and phenylimidazole-inhibited complexes of cytochrome P-450cam , 1993 .
[4] D. Lewis,et al. Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. , 1998, Mutation research.
[5] B. Erdmann,et al. Human adrenal CYP11B1: localization by in situ-hybridization and functional expression in cell cultures. , 1995, Endocrine research.
[6] D S Moss,et al. Main-chain bond lengths and bond angles in protein structures. , 1993, Journal of molecular biology.
[7] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[8] U. Heinemann,et al. Adrenodoxin: Structure, stability, and electron transfer properties , 2000, Proteins.
[9] S. Imaoka,et al. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. , 2001, Endocrinology.
[10] Nico P. E. Vermeulen,et al. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building , 1993, J. Comput. Aided Mol. Des..
[11] Ferran Sanz,et al. Three-dimensional modelling of human cytochrome P450 1A2 and its interaction with caffeine and MeIQ , 1997, J. Comput. Aided Mol. Des..
[12] J. Halpert,et al. Distinct binding of cholesterol and 5β-cholestane-3α,7α,12α-triol to cytochrome P450 27A1 : Evidence from modeling and site-directed mutagenesis studies , 2006 .
[13] R. Brueggemeier,et al. The final catalytic step of cytochrome p450 aromatase: a density functional theory study. , 2005, Journal of the American Chemical Society.
[14] H. Dörr,et al. Etomidate: A selective adrenocortical 11β-hydroxylase inhibitor , 1984, Klinische Wochenschrift.
[15] Joël Ménard,et al. The 45-year story of the development of an anti-aldosterone more specific than spironolactone , 2004, Molecular and Cellular Endocrinology.
[16] A. Cavalli,et al. Linking CoMFA and protein homology models of enzyme-inhibitor interactions: an application to non-steroidal aromatase inhibitors. , 2000, Bioorganic & medicinal chemistry.
[17] K. Yanagibashi,et al. The synthesis of aldosterone by the adrenal cortex. Two zones (fasciculata and glomerulosa) possess one enzyme for 11 beta-, 18-hydroxylation, and aldehyde synthesis. , 1986, The Journal of biological chemistry.
[18] R. Bernhardt,et al. Modelling of three-dimensional structures of cytochromes P450 11B1 and 11B2. , 2001, Journal of inorganic biochemistry.
[19] B. Pitt,et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.
[20] Andrea Brancale,et al. Homology model of 1α,25-dihydroxyvitamin D3 24-hydroxylase cytochrome P450 24A1 (CYP24A1): Active site architecture and ligand binding , 2007, The Journal of Steroid Biochemistry and Molecular Biology.
[21] J. Salerno,et al. Molecular modeling of the 3-D structure of cytochrome P-450scc. , 1992, Biochimica et biophysica acta.
[22] Laxmikant V. Kalé,et al. Scalable molecular dynamics with NAMD , 2005, J. Comput. Chem..
[23] B. Pitt,et al. Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction , 2003 .
[24] S. Ekins,et al. Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[25] R. Bernhardt,et al. Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones. , 1998, European journal of biochemistry.
[26] J. Peterson,et al. How similar are P450s and what can their differences teach us? , 1999, Archives of biochemistry and biophysics.
[27] G H Loew,et al. Construction of a 3D model of cytochrome P450 2B4. , 1997, Protein engineering.
[28] M. Okamoto,et al. Functional expression of the cDNAs encoding rat 11β-hydroxylase [cytochrome P450(11β)] and aldosterone synthase [cytochrome P450(11β, aldo)] , 1991 .
[29] M. Okamoto,et al. Frog cytochrome P-450 (11 beta,aldo), a single enzyme involved in the final steps of glucocorticoid and mineralocorticoid biosynthesis. , 1995, European journal of biochemistry.
[30] N. Ibrahim,et al. Aromatase inhibitors in breast cancer: an overview. , 2006, The oncologist.
[31] R. Hartmann,et al. Discovery of selective CYP11B2 (aldosterone synthase) inhibitors for the therapy of congestive heart failure and myocardial fibrosis. , 2003, European journal of medicinal chemistry.
[32] A. Warshel,et al. Examining methods for calculations of binding free energies: LRA, LIE, PDLD‐LRA, and PDLD/S‐LRA calculations of ligands binding to an HIV protease , 2000, Proteins.
[33] L. Nieman,et al. The Metyrapone and Dexamethasone Suppression Tests for the Differential Diagnosis of the Adrenocorticotropin-Dependent Cushing Syndrome: A Comparison , 1994, Annals of Internal Medicine.
[34] M. Okamoto,et al. Synthesis of aldosterone by a reconstituted system of cytochrome P-45011 beta from bovine adrenocortical mitochondria. , 1985, Journal of biochemistry.
[35] G. N. Ramachandran,et al. Conformation of polypeptides and proteins. , 1968, Advances in protein chemistry.
[36] M. Saraste,et al. FEBS Lett , 2000 .
[37] Jürgen Pleiss,et al. Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: The molecular basis of substrate binding and regioselectivity toward warfarin , 2006, Proteins.
[38] H. Schrauber,et al. Engineering a Mineralocorticoid- to a Glucocorticoid-synthesizing Cytochrome P450 (*) , 1996, The Journal of Biological Chemistry.
[39] 김삼묘,et al. “Bioinformatics” 특집을 내면서 , 2000 .
[40] A. Matter,et al. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo. , 1988, Cancer research.
[41] D. Koop,et al. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. , 1994, The Journal of pharmacology and experimental therapeutics.
[42] Alexander D. MacKerell,et al. All-atom empirical potential for molecular modeling and dynamics studies of proteins. , 1998, The journal of physical chemistry. B.
[43] D. Duprez,et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. , 2002, Journal of the American College of Cardiology.
[44] A. J. Byrne,et al. Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. , 1983, British medical journal.
[45] J. Connell,et al. The new biology of aldosterone. , 2005, The Journal of endocrinology.
[46] J. Doehmer,et al. Cloning of CYP11B1 and CYP11B2 from normal human adrenal and their functional expression in COS-7 and V79 Chinese hamster cells. , 1995, Endocrine research.
[47] J. Peterson,et al. Cholesterol binding to cytochrome P450 7A1, a key enzyme in bile acid biosynthesis. , 2005, Biochemistry.
[48] J. Peterson,et al. A close family resemblance: the importance of structure in understanding cytochromes P450. , 1998, Structure.
[49] R. Estabrook,et al. Probing the interaction of bovine cytochrome P450scc (CYP11A1) with adrenodoxin: evaluating site-directed mutations by molecular modeling. , 2002, Biochemistry.
[50] Thomas Lengauer,et al. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. , 2005, Journal of medicinal chemistry.
[51] J. López-Sendón,et al. The EPHESUS Trial: Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction , 2004, Cardiovascular Drugs and Therapy.
[52] H. Krum,et al. Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients , 2002, Hypertension.
[53] D. Sica. Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis , 2005, Heart Failure Reviews.
[54] M. Seldin,et al. Different isozymes of mouse 11 beta-hydroxylase produce mineralocorticoids and glucocorticoids. , 1991, Molecular endocrinology.
[55] P. Furet,et al. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. , 1993, Journal of medicinal chemistry.
[56] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[57] M. Murray,et al. Mechanisms of the inhibition of cytochrome P-450-mediated drug oxidation by therapeutic agents. , 1987, Drug metabolism reviews.
[58] Hans-Dieter Höltje,et al. Molecular design of two sterol 14α-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole , 2005, J. Comput. Aided Mol. Des..
[59] Richard D. Taylor,et al. Improved protein–ligand docking using GOLD , 2003, Proteins.
[60] A. Cavalli,et al. Nonsteroidal aromatase inhibitors: Recent advances , 2002, Medicinal research reviews.
[61] R. Raag,et al. Cytochrome P450cam: crystallography, oxygen activation, and electron transfer1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] C. Delcayre,et al. Cardiac aldosterone production and ventricular remodeling. , 2000, Kidney international.
[63] R. Santen,et al. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. , 1990, The Journal of clinical endocrinology and metabolism.
[64] J. Liu,et al. Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. , 1998, Archives of biochemistry and biophysics.
[65] O. Gotoh,et al. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.
[66] A. Struthers. Aldosterone: cardiovascular assault. , 2002, American heart journal.
[67] J. O. Johnston,et al. Enzyme-activated inhibitors of steroidal hydroxylases , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[68] J Deisenhofer,et al. Structure and function of cytochromes P450: a comparative analysis of three crystal structures. , 1995, Structure.
[69] Toshimasa Tanaka,et al. Characterization of the CYP3A4 active site by homology modeling. , 2004, Chemical & pharmaceutical bulletin.
[70] O. Weinberg,et al. New approaches to reverse resistance to hormonal therapy in human breast cancer. , 2005, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[71] T. Yeates,et al. Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.
[72] Geoffrey J. Barton,et al. JPred : a consensus secondary structure prediction server , 1999 .
[73] D. Case,et al. Optimized particle-mesh Ewald/multiple-time step integration for molecular dynamics simulations , 2001 .
[74] K. Nakao,et al. Cloning of cDNA and genomic DNA for human cytochrome P‐45011β , 1990, FEBS letters.
[75] 國郎 小笠原,et al. Chem. Pharm. Bull.(オピニオン) , 2007 .